Quantcast
Home > Quotes > GH

Guardant Health, Inc. Common Stock (GH) Quote & Summary Data

GH 
$88.08
*  
3.15
3.45%
Get GH Alerts
*Delayed - data as of Mar. 20, 2019  -  Find a broker to begin trading GH now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
82
Today's High / Low
$ 91.24 / $ 87.04
Share Volume
813,542
50 Day Avg. Daily Volume
638,467
Previous Close
$ 91.23
52 Week High / Low
$ 106.58 / $ 27.04
Market Cap
7,560,122,548
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0

Intraday Chart

Shares Traded

Share Volume:
813,542
50 Day Avg. Daily Volume:
638,467

Trading Range

The current last sale of $88.08 is 225.74% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 91.24 $ 106.58
 Low: $ 87.04 $ 27.04

ETFs with GH as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
3.37% SPDR S&P Health Care Services ETF (XHS) -5.76 (-7.90%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a leading precision oncology company focused on helping conquer cancer globally through use of our proprietary blood tests, vast data sets and advanced analytics. We believe that the key to conquering cancer is unprecedented access to its molecular information throughout all stages of the disease, which we intend to enable by a routine blood draw, or liquid biopsy. Our Guardant Health Oncology Platform is designed to leverage our capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of our goal to manage cancer across all stages of the disease, we have launched our liquid biopsy tests, Guardant360 and GuardantOMNI, for advanced stage cancer, which fuel our programs developing tests for recurrence and early detection, LUNAR-1 and LUNAR-2, respectively.  ... More ...  



Risk Grade

Where does GH fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 91.09
Open Date:
Mar. 20, 2019
Close Price:
$ 88.08
Close Date:
Mar. 20, 2019


Consensus Recommendation

Analyst Info